Information Provided By: 
Fly News Breaks for September 13, 2019
CYTK
Sep 13, 2019 | 07:18 EDT
JMP Securities analyst Jason Butler raised his price target on Cytokinetics to $23 and kept his Buy rating, saying the company's upcoming presentation of its CK-274 phase 1 study results at the 2019 HFSA Scientific Meeting this weekend offer an "an opportunity to confirm differentiated pharmacology and highlight the agent's value proposition". The analyst adds that he is specifically looking to confirm a shorter half live in the trial relative to mavacamten's 7-day period.
News For CYTK From the Last 2 Days
CYTK
Apr 26, 2024 | 16:10 EDT
In a regulatory filing, Cytokinetics disclosed that on April 23, the company entered into an employment offer letter with Sung Lee, pursuant to which Lee has agreed to serve as the company's Executive Vice President, CFO, effective as of May 8. On the start date, Lee will assume the duties and responsibilities of the company's principal financial officer from Robert Blum, the company's President and CEO, who has been serving as the company's principal financial officer on an interim basis
